['salivary gland tumors', 'head and neck cancer']
['cisplatin', 'docetaxel']

        Inclusion Criteria:

          1. Pathologically proven diagnosis of a malignant salivary gland tumor of intermediate or
             high-grade

          2. Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 5mm) or microscopically
             positive surgical margin

          3. Surgical resection with curative intent within 8 weeks prior to registration, with no
             evidence of gross tumor residual

          4. No evidence of distant metastases

          5. No synchronous or concurrent head and neck primary tumors

          6. Karnofsky score over 60

          7. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) >= 1.5 * 10^9/l

               2. Platelets count >= 100 * 10^9/l

               3. Hemoglobin >= 10 g/dl

               4. AST and ALT <= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin <= 1.5 times institutional ULN

               6. Creatinine clearance >= 50 ml/min

               7. Serum creatine <= 1 times ULN

          8. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
      